A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
May 13, 2025
End Date
May 11, 2030
Awarded By
Amgen, Inc.
Start Date
May 13, 2025
End Date
May 11, 2030